Therapeutic Vaccine Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Therapeutic Vaccines Market Analysis is segmented By Type (Antigen Vaccines, Dendritic Cell Vaccine, DNA Vaccine, Tumor Cell Vaccines), By Products (Autoimmune Disease Vaccine, Addiction Vaccine, Cancer Vaccines, Neurological Disease Vaccine, Infectious Disease Vaccine, Others), By Technology (Autologous Vaccines, Allogeneic Vaccines), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Therapeutic Vaccines Market Overview

Global Therapeutic Vaccines Market is expected to reach at a high CAGR during the forecast period 2024-2031.

Therapeutic vaccination is one that is taken after infection to induce antiviral immunity and thereby change the course of the disease. It’s ultimate goal is to change host immunity in order to eradicate disease and develop long-term memory.

The rapid advancement of nanobiotechnology has allowed for advancements in therapeutic cancer vaccinations. A therapeutic cancer vaccine's primary purpose is to elicit a cellular immune response, including the activation of killer T cells.

Therapeutic Vaccines Market Scope

For more details on this report Request for Sample

Therapeutic Vaccines Market Dynamics

Increase in the prevalence of infectious diseases

The increase in infectious diseases has impacted the lives of a number of people. In order to prevent infections a number of new therapeutic vaccines have been introduced. The increase in innovations of therapeutic vaccines is expected to drive market growth. 

For instance, according to the Centers for Disease Control (CDC), it is estimated that each year, up to 400 million people get infected with dengue. Approximately 100 million people get sick from infection, and 40,000 die from severe dengue. 

Additionally, according to the report by World Health Organization (WHO), it is stated that researchers have estimated that every year, there are 1.3 to 4.0 million cases of cholera, and 21 000 to 143 000 deaths worldwide due to the infection. Cholera is considered an extremely serious disease that can cause severe acute watery diarrhea with severe dehydration.

The increase in the number of infectious diseases will increase the demand for therapeutic vaccines in order to treat infectious diseases by developing an immune response against the antigens present.

Restraint

Huge capital expenditure on vaccine development, the rising cost of research and development (R&D), biological and technical challenges associated with targeting more complex diseases, competition with better standards of care, the larger scale of clinical studies to prove safety and efficacy, and stringent regulations are the factors the market is expected to get hampered in the forecast period.

Therapeutic Vaccines Market Segmentation Analysis

The global therapeutic vaccines market is segmented based on type, products, technology, distribution channel and region.

Cancer vaccines segment accounted for 38.3% of the market share 

The ability to deliver all potential antigens to the immune system is the most essential advantage of cancer vaccines. Cancer vaccines, either allogeneic or autologous, can be created and delivered to patients using irradiation of whole cells or cell lysates.

Cancer vaccines segment has been holding a dominant segment in the therapeutic vaccines market due to the rise in the number of different cancers that can be treated through therapeutic vaccines. It is expected to continue throughout the forecast period. For instance, according to the American Society of Cancer, it is estimated that about 288,930 new cancer cases are to be diagnosed. 

Additionally, it is estimated that about 82,290 new bladder cancer cases and 97,610 melanoma cases are to be diagnosed in the year 2023. The availability of tumor cell vaccines is expected to treat cancers. Thus, an increase in the incidence of cancer cases is expected to raise the growth of the segment.

Therapeutic Vaccines Market Geographical Share

North America is expected to hold a significant position in the global therapeutic vaccines market share

North America is a dominant force in the global therapeutic vaccine market. The rising incidence of chronic infectious diseases, cancer, and Alzheimer’s, are the factors that are driving the market growth. It is expected to continue throughout the forecast period.

According to Alzheimer's San Diego Organization, it is estimated that at least one person in America develops Alzheimer's every 67 seconds. It is estimated that nearly 500,000 new cases of Alzheimer's disease will be diagnosed in 2023.

Additionally, according to the American Society of Cancer, it is estimated that about 81,800 new cases of kidney cancer will be diagnosed. Thus, an increase in disease conditions is expected to increase the demand for therapeutic vaccines. 

Also, the presence of key manufacturers, increasing investments by pharmaceutical companies for vaccine development in the region, proactive government initiatives, favorable subsidiaries, and a large patient pool are driving the market in North America.

COVID-19 Impact Analysis

COVID-19 has impacted the growth of the market positively. There is a rise in the demand for therapeutic vaccines during this period. The increase in the cases of COVID-19 has increased the emergency and demand for the production of therapeutic vaccines which have the ability to produce antibodies against the virus. 

Therapeutic Vaccines Companies

The leading companies with a significant market share in global therapeutic vaccines include Elicio Therapeutics, Argos Therapeutics, CSL Limited, Johnson & Johnson, AstraZeneca Plc, Merck & Co., Inc., Eli Lilly and Company, Sanofi, Dynavax Technologies., and GSK Pharmaceuticals among others.

Key Developments

• On January 24, 2023, the Serum Institute of India (SII) launched India's First Indigenously Made Cervical Cancer Vaccine 'CERVAVAC'.
• On May 11, 2023, TechInvention Lifecare India in partnership with Eubiologics Co, South Korea, launched Euvichol-Plus, an oral cholera vaccine in India.

Why Purchase the Report?

• To visualize the global therapeutic vaccines market segmentation based on type, products, technology, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development. 
• Excel data sheet with numerous data points of therapeutic vaccines market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.

The global therapeutic vaccines market report would provide approximately 69 tables, 70 figures, and 183 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies